However, lenalidomide (LEN) refractoriness remains an important factor affecting the therapeutic efficacy of both PI and IMiD (Table 1), even after another class of anti-myeloma therapeutics, such as anti-CD38 MoAbs, are available. Here, CD38 is linked to plasma cell myeloma.